GHRH antagonists, in addition to their indirect antitumor effects through the GHRH- pituitary GH-hepatic insulin-like growth factor-I (IGF-I) axis, were shown to directly inhibit the proliferation of human cancer cell lines in vitro [9,10,11]. The gene discussed is GHRH; the disease is cancer.